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ABSTRACT 
The scientific way to develop an easy and robust analytical technique for critical analysis is a QbD approach. QbD is a systematic approach to 
product or method development that begins with predefined objectives and uses science and risk management approaches to achieve product 
and method understanding and ultimately method control. The aim of the analytical QbD is to achieve quality in measurement. The main 
objective of this review to explain different steps involved in method development by the QbD approach for analytical method development and 
describes the implementation of QbD in analytical procedure validation. The advantages of applying QbD principles to analytical technique 
include discovering and minimizing the source of variability that may lead to poor method robustness and ensuring that the method meets its 
intended performance need throughout the product and method lifecycle. 
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The concept of Quality by Design (QbD) was first developed 
by Dr. Joseph M. Juran in various publications, he called that 
quality could be planned. ICH Q8 guidelines were mentioned 
the concept of QbD, which state that “Quality should be built 
into the product by design but quality cannot be tested in the 
product”. Quality is the suitability of either a drug substance 
or a drug for its intended uses. This term includes such 
attributes as the identity, purity, and strength. According to 
ICH Q8 (R1) Quality by design is “a systematic approach to 
development that begins with a predefined objective and 
emphasizes product and process understanding and process 
control, based on sound science and quality risk 
management”.To achieve the quality in measurement is the 
main purpose of analytical of QbD.[1] Benefits of 
implementing AQbD is through an understanding of 
attributes of method. Enhanced knowledge sharing, 
development of the high-performance method, dynamic 
control strategy leads to greater efficient regulatory 
oversight, operative elasticity, regulatory filing based on 
science and automatic rational, improve timing to reach the 
market, reduce consumer-generic agnosticism, fantabulous 
return on investment, limited product rejects and reduce 
post-approval change.  Analytical methods are a 
fundamental part of the control strategy in the 
pharmaceutical quality system (ICH Q10). It includes many 
parameters and attributes related to drug substance and 
drug products i.e. instrument operating condition and their 
associated method.[2] 
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Fig 1: The Life cycle of quality by design approach (QbD) 
 
Advantages of QbD:  
 It provides better flexibility in decision making. 
 It increases opportunities for life cycle approval. 
 Reduce batch failure. 
 It helps design for unmet medical need. 
 Better knowledge of the process.  
 Better quality of the review. 
 It allows for continuous improvement until the end 
step of the method. 
 Reduce deviation and costly investigation. 
 It affects product design and process development. 
 Reducing variability in the analytical attribute for 
improving the method robustness.[3] 
 
Table 1: Difference between conventional approaches and QbD approaches. 
Parameters Conventional approaches QbD approaches  
Approaches Based on empirical approaches Based on systematic approaches 
Quality  Quality assurance including final product testing and 
inspection. 
Quality is maintained throughout the 
method development phase 
Method  Fix, change cannot support Flexible, it allows continues improvement 
Reliability  Based on batch trial and validation report Based on method performance to ATP  
criteria  
Submission Submission only data Submission with product designing and 
knowledge 
Cost  If any change to occur in the process involve hug lose in 
cost 
Cost effective method 
 
Analytical method development strategies: [4] 
The main application of quality by design (QbD) principles 
for development of analytical method is focused on the 
principle of building quality into the analytical method 
during its development. Because of this, the actual method 
development process for an analytical quality by design 
(QbD) method should follow a structured approach. The aim 
of the QbD method development is comply with predefined 
objectives. The objective of the QbD method development 
can be illustrated using HPLC an example. The aim of the 
HPLC method for API is generally to separate and quantify 
the main compound and the critical quality attributes (CQA0) 
that may impact the quality of the drug product. The 
specifications should meet regulatory requirements such as 
specificity, linearity, accuracy, precision, robustness and 
ruggedness.   
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Fig 2: A schematic representation of method development strategies for analysis of impurity through different analytical 
techniques [4] 
 
Steps of QbD approach in analytical method 
development:  
 
Fig.3: Different steps of quality by design QbD 
1. Analytical target profile (ATP): 
QbD is beginning with an analytical target profile, which is a 
linear to QTPP. Analytical target profile defines the aim of 
the analytical method development process, relating the 
results of the method to attain QTPP. ATP describes the 
method requirements which are expected to be the 
measurement. The analytical target profile is specifying with 
the help of knowledge and scientific reason of the analytical 
process. The ATP defines to what level the measurement is 
needed (i.e. functioning level characteristics, such as 
precision, accuracy, range, and sensitivity) and what the 
method has to measure (i.e. acceptance criteria). [5] 
Generally, ATP for analytical procedure contains a selection 
of target analytic (API and impurities), selection of analytical 
technique (HPLC, HPTLC, gas chromatography, ion 
chromatography, etc.) and method requirements (assay and 
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Specificity  The ability to assess unequivocally the analyte in the presence of other components 
that may be expected to be present  
Linearity  Ability to elicit test results that are directly or by well defined mathematical 
transformation, proportional to the concentration of an analyte in the sample 
within a given range  





Limit of detection 
(LOD) 
Characteristics of the limit test: the lowest amount of analyte in the sample can be 
detected  
Limit of quantitation 
(LOQ) 
The lowest amount of analyte in a sample that can be determined with acceptable 
precision and accuracy  
Range  The interval between upper and lower levels of analyte that have been 
demonstrated to be determined with a suitable level of precision, accuracy, and 
linearity  
N/A 
Robustness Capacity to remain unaffected by small but deliberate variations in procedural 
parameters listed in the procedure documentation and provide an indication of its 
suitability during normal range  
N/A 
 
2. Critical quality attributes (CQA): 
CQA is the second step of QbD. According to ICH Q8, CQA is 
defined as a physical, chemical, biological property that 
should be within an appropriate limit, range to ensure the 
desired product quality. (8)CQA for analytical method 
consists of method parameters and method attributes. The 
analytical technique of CQA can differ from one to another. 
 CQA for the GC method is the temperature of the oven 
and its program, injection temperature, gas flow rate, 
sample diluents, and concentration. 
 CQA for the HPLC method is mobile phase buffer, pH of 
the mobile phase, column selection, organic modifier, and 
elution method. 
 CQA for HPTLC method is TLC plats, mobile phase, 
Injection concentration and volume, time taken for plate 
development, a reagent for color development and 
detection. [8-9] 
3. Risk assessment: 
When CQA has been studied, the next step is to describe the 
relevant risk assessment. Once the technique is identified, 
analytical QbD focuses on the assessment of the risk 
associated with variability includes analyst method, 
instrument configuration, measurement and method 
parameters, sample characteristics, Sample preparations, 
and environmental conditions. [10] 
According to ICH Q9 guidelines, risk assessment is a 
systematic process for the assessment, control, 
communication and review of risk to the quality across the 
product lifecycle. Risk identification, risk analysis, and risk 
evaluation are the three-step of risk assessment. [11] 
 
 
Fig 4: Different steps of risk assessment. 
 
The first step of risk assessment is very important to identify 
and prioritize potential risk. These risks include methods of 
operation of the instrument, characteristics of reagent and 
cycle time. It is the most desirable to determine a contingent 
method in case the primary method fails. Flow chart and 
check list are used to describe the risk factor.   
The second step of risk assessment is risk evaluation. 
Fishbone diagram is used to perform risk assessment, also 
called Ishikawa. According to this approaches the risk factor 
is divided into three categories- high-risk factor, noise factor 
and experimental factor. [12] 
 
Singh et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):1006-1012 
ISSN: 2250-1177                                                                                [1010]                                                                                     CODEN (USA): JDDTAO 
 
Fig 4: Ishikawa cause-and-effect fish-bone diagram for a liquid chromatographic method development 
The highest identified risk related to the stability of the 
sample and standard. Stability of the samples and standards 
to be evaluated and also to be focused on the level of related 
substances in standard and samples. The sample or standard 
may absorb the water during weighing which could be 
considered as the second highest identified risk
.  
Table 3: Risk assessment and control strategy [13] 
Potential failure 
cause 
Failure effect Risk mitigation P S D Total 
Water source Change the peak resolutions 
S/N 
Compare mobile phase from each lab 
during precision testing 
2 1 1 2 
Sample stability Changes in peak resolutions 
S/N 
ascertain the stability of prepared sample 
solutions during the validation study 
2 1 2 2 
Standard Changes in the standard 
potency and purity 
ascertain the stability of prepared standard 
solutions during the validation study 
1 4 5 20 
Mobile phase 
stability 
Changes to chromatography Establish the stability of prepared 
samples/solutions during the validation 
study 
2 1 2 2 
Columns Lot variability may change 
in peak resolutions S/N 
Evaluate at least two different loads 2 1 1 2 
Reagents Lot variability may change 
in peak resolutions S/N 
Perform evaluation during the study 3 1 1 3 
Vials Exposure to light results in 
an increase of impurity  
Amber vials to be used. Use same vials for 
standard and reference 
1 3 1 3 
Humidity Humidity changes in the 
laboratory may result in 
accurate weighing  
Standard operating procedures to be 
followed to dry the samples and standard 
1 4 3 12 
Column 
temperature 
Changes in the laboratory 
temperature may change 
the peak resolutions S/N 
Study and control column temperature if 
required 
3 1 1 3 
Sample 
temperature 
May change the peak 
resolutions S/N 
Study and control autosampler 
temperature if required 
3 1 3 3 
Sample/standard 
light exposure 
May cause changes in the 
purity of sample/standards 
Use amber vials and use the same 
conditions for sample and standards 
 
2 3 1 6 
Sampling rate May cause changes in the 
purity and potency values 
Control in HPC within the specified range 1 1 1 1 
Misidentification of 
peaks 
Incorrect values reported 
for known impurities 
Training, example chromatograph 4 2 1 8 
Instrument model Changes to peak resolution 
S/N 
Previous studies obtained acceptable LOQ 
on two HPLC/UV model 
1 1 1 1 
S/N= Signal to noise, P=Probability, S=Sevierity, D=Detectability 
The risk assigned to each failure modes was calculated as Risk= Severity X Probability X Delectability and calculated as risk 
priority number (RPN) 
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4. Method operational design region: 
Once method development and risk assessment have been 
identified the next step is method operational design region. 
MODR is used to method development operational region for 
daily operation. MODR is based on science, risk-based and 
multivariate approach to measuring the effect of various 
factors on method performance. It is also used to set up 
important method control such as system suitability, RRT 
and RRF. [14] 
5. Control strategy:  
The control strategy is the control design set. It is calculated 
from the analyst nature and MODR understanding. The 
method control strategy can be set up on complete statistical 
data collected during the MODR. The control strategy is not 
forever a onetime practice that is performed during the 
method development phase but it can get changes with 
different phases of the method lifecycle. It is noted that the 
method control strategy of QbD approaches does not differ 
from conventional approaches. [15] 
6. Lifecycle management: 
Lifecycle management is the last step of QbD. It is a continues 
process of sharing knowledge gain during the method 
development phase includes the final result of risk 
assessment, assumption based anterior knowledge, MODR, 
control strategy CQA and analytical target profile. The 
lifecycle management of QbD approaches different from 
conventional approaches.  
7. Experimental design 
The experimental design is a statistical approach to 
systematize the experiments so that the requisite 
information is obtained precisely and efficiently, before the 
conduct of experimental studies.  Prior to the selection of an 
apt experimental design, it is important to demarcate the 
experimental domain or region of interest within a factor 
space. [16] 
7.1 Design of experiments:  
The process of determining the most suited composition and 
operating conditions is called optimization. The term 
optimizes literally means to bring something as close to 
perfection as possible. A number of variables are involved in 
the design and development of pharmaceuticals. The 
variables that can be controlled by the manufacturer are 
called independent variables/factors and these independent 
variables have the potential to influence the characteristics 
of the analytical method and outputs. Levels are the values of 
the factors. The properties exhibited by finished products are 
termed as response variables or dependent variables. Any 
change in independent variables leads to a corresponding 
change in the dependent variables. [17] 
The different types of Design of Experiments (DoE) 
optimization methodologies have been illustrated in Figure 
4. DoE has evolved into a powerful tool that elegantly 
provides a large number of information with the least runs  
 
Fig 5: Design of experiments (DoE) optimization 
methodologies
 
Table 4: Quality by design vital terminology 
Term  Definition  
Optimize  Make as perfect, effective, or functional as possible  
Optimized  
Improved product to accomplish the objectives of a development scientist using DoE and 
computers  
Optimization  
Implementation of systematic approaches to achieving “the best” combination of product 
and/or process characteristics under a given set of conditions  
Independent Variables  Input variables, which are directly under the control of the product development scientist  
Quantitative Variables  Variables that can take numeric values 
Categorical Variables  Qualitative variables which can not be quantified  
Runs or  Trials  Experiments conducted according to the selected experimental design 
Factors  
Independent variables, which influence the product/process characteristics or output of the 
process 
Design Matrix  The layout of experimental runs in matrix form, as per experimental design 
Knowledge Space  
Scientific elements to be considered and explored on the basis of previous knowledge as 
product attributes and process parameters  
Design Space  
Multidimensional combination and interaction of input variables and process parameters 
demonstrated to provide quality assurance 
Control Space  The domain of design space selected for the detailed study  
Critical Quality Attributes 
(CQA)  
Parameters ranging within appropriate limits, which ensure the desired product quality 
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